Work

A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.9001

Authors: R. D. Carvajal, P. B. Chapman, J. D. Wolchok, L. Cane, J. B. Teitcher, J. Lutzky, A. C. Pavlick, B. C. Bastian, C. R. Antonescu, G. K. Schwartz

Institutions: Memorial Sloan Kettering Cancer Center, University of California, San Francisco, New York University

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1799547826

Cites:

Cited by: 58

Related to: 10